tm logo
AVRILLA
Live/Pending
FIRST EXTENSION - GRANTED

granted

on 04 Jan 2024

Last Applicant/ Owned by

Building A

Parsippany

NJ

07054

Serial Number

97491607 filed on 06th Jul 2022

Registration Number

N/A

Correspondent Address

Laurence Rickles

TEVA PHARMACEUTICALS USA, INC.

400 Interpace Parkway, Building A

Parsippany,NJ 07054

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

AVRILLA

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and t Read More

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations, namely, oral and injectable contraceptives, women's hormone replacement medications

Mark Details


Serial Number

No 97491607

Mark Type

No Service/Collective Mark

Attorney Docket Number

No TEV0975TUS

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
06th Jan 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04th Jan 2024SOU TEAS EXTENSION RECEIVED
04th Jan 2024SOU EXTENSION 1 FILED
04th Jan 2024SOU EXTENSION 1 GRANTED
04th Jul 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
09th May 2023PUBLISHED FOR OPPOSITION
09th May 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19th Apr 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
31st Mar 2023APPROVED FOR PUB - PRINCIPAL REGISTER
28th Mar 2023ASSIGNED TO EXAMINER